New results to be Presented at The BRAIN Foundation Synchrony 2020 Conference

STALICLA will present new data from the biological characterization of a novel DEPI-identified endophenotype within Autism Spectrum Disorder (ASD): ASD Phenotype 1 (ASD-Phen1) at The BRAIN Foundation Synchrony 2020 conference Dec. 12th 2020

Read more

The three clinical trials currently led by STALICLA now on the portal of the World Health Organization (WHO) and of

STALICLA is now enrolling patients with ASD Phenotype 1 in the first interventional trial with STP1 in this biologically-defined subpopulation (NCT04644003). STALICLA is also conducting two observational studies (NCT04600882 and NCT04273087) to identify new subgroups of patients within the autism spectrum. 

Read more

STALICLA presenting its approach and results at Annual Swiss Symposium in Pharmaceutical Medicine

Tackling the challenges of precision medicine in Neuropsychiatry

Read more

STALICLA becomes a clinical stage company, with the approval of its STP1 investigational new drug (IND) application by the FDA

STP1 is the first precision treatment to enter the clinic for a biologically-defined subgroup of patients with autism spectrum disorder.

Read more

Search for content on Stalicla...